Team
Peter H. Krammer, MD
48 years Experience in Science Management:
Head of the Division of Immunogenetics at the DKFZ , Heidelberg, Germany, Speaker of the Tumorimmunology Program at the DKFZ, Co-Founder of APOGENIX Biotech Company, Speaker of the Helmholtz Alliance Immunotherapy of Cancer, Member of the Board of Directors NCT Heidelberg
Multiple scientific prizes (e.g Robert Koch, Kitasato Behring, Ernst Jung, German Cancer)
Björn Cochlovius, Ph.D
26 years Experience in Academia and Industry (R&D, Strategy, Business):
Head Dept. Recomb. Antibodies DKFZ; Head R&D Affitech; CEO OnTarget Therapeutics; Director Business Dev. Roche; Interim-CEO Ciliatech; Head Oncology Otsuka NP; Head Development Japan-Asia-Pacific Abbvie; Chairman of Isogenica (Cambridge, UK), Board Director at Karolinska Development.
Heiko Weyd, Ph.D
20 years of Experience in Research with Focus on the Annexin Checkpoint System:
Head of the Annexin Immunoregulation Group, German Cancer Research Center DKFZ, Heidelberg - Development of Purification Methods, Activity Assays and Establishment of in vivo Mouse Models (Tumor, Allergy, and others).
Xin Liu, M.Sc.
20 years in Pharma industry and Venture Capital/Private Equity:
Master thesis with Prof. Rajewsky (Cologne University). Senior positions in corporate M&A, Business Development and Marketing/sales with GSK, Roche and Eli Lilly. Co-founded or seed founded more than 10 Biotech start-ups. Managing Director and head of GPC Capital, China. Board Director at Tasly Pharma and AmeriGen.